•EIFFELVET
EIFFELVET Herceptin 1998
Trastuzumab
K sein
MAB
NIB
Erbitux 2004
Cetuximab
K colon
Avastin 2004
Bevacizumab
K colon
EIFFELVET
AC monoclonal et Lymphome Canin
AC CD20 Lymphome B
AC CD 52 Lymphome T
“Treatment of Canine B-cell Lymphoma with Doxorubicin With or Without an
Anti-CD20 Monoclonal Antibody: An Open-Label Pilot Study,” Dr. Julie
Bulman-Fleming. VCS Saint Louis 10/14
“Treatment of Canine B-Cell Lymphoma with Chemotherapy and a Canine Anti-
CD20 Monoclonal Antibody: A Prospective Double-Blind, Randomized, Placebo-
Controlled Study,” Dr. Gregory Ogilvie VCS Saint Louis 10/14
EIFFELVET
lymphoma cell
CD45
Anti-CD45 mAb
211Astatine
Radio immunothérapie
Essai clinique en cours
Oregon State University
Pr Stuart Helfand
EIFFELVET
α- versus β-emitters
Normal tissueVessel, marrow
Short path length
High linear energy transfer
(LET)
Short half-life
Favorable properties of α-emitters
α-particle
β-particle
Radio Immunothérapie
Anticorps monoclonal couplé à un émetteur alpha
But: limiter la chimiothérapie
intensive
But: limiter la radiothérapie
Corps entier